Phase I and pharmacological study of a new camptothecin derivative, exatecan mesylate (DX-8951f), infused over 30 minutes every three weeks

Clinical Cancer Research

Volumn 7, Issue 10, 2001, Pages 3056-3064

  Minami, Hironobu ^a   Fujii, Hirofumi ^a   Igarashi, Tadahiko ^a   Itoh, Kuniaki ^a   Sasaki, Yasutsuna ^a   Tamanoi, Kyoji ^b   Oguma, Toshihiro ^b  

^a Division of Oncology/Hematology   (United States)

^b Daiichi Pharmaceutical Co   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN DERIVATIVE; DRUG METABOLITE; EXATECAN; LACTONE;

ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG INFUSION; DRUG METABOLISM; DRUG TOLERABILITY; DRUG URINE LEVEL; FEMALE; HUMAN; LIVER DYSFUNCTION; MALE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; VOMITING;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; CAMPTOTHECIN; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS; NEUTROPENIA; THROMBOCYTOPENIA; TIME FACTORS; TREATMENT OUTCOME; VOMITING;

EID: 0034796438     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I
2. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin
3. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11
4. Clinical applications of the camptothecins
5. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer
6. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer
7. Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial
8. Randomized trial comparing cisplatin (CDDP) and irinotecan (CPT-11) versus CDDP and vindesine (VDS) versus CPT-11 alone in advanced non-small cell lung cancer (NSCLC), a multicenter Phase III study
9. Impact of irinotecan (CPT-11) and cisplatin (CDDP) on survival in previously untreated metastatic non-small cell lung cancer (NSCLC)
10. Randomized Phase III study of irinotecan (CPT-11) and cisplatin versus etoposide and cisplatin in extensive-disease small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG9511)
11. Clinical pharmacokinetics of irinotecan
12. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
13. Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGTIA-1 promoter polymorphism
14. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: A pharmacogenetic analysis
15. A new water-soluble camptothecin derivative, DX-8951f, exhibits potent antitumor activity against human tumors in vitro and in vivo
16. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice
17. The topoisomerase I inhibitor DX-8951f is active in a severe combined immunodeficiency mouse model of human acute myelogenous leukemia
18. Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice
19. Comparison of DX-8951f and topotecan effects on tumor colony formation from freshly explanted adult and pediatric human tumor cells
20. Antitumor activity of DX-8951f: A new camptothecin derivative
21. DX-8951f, a water-soluble camptothecin analog, exhibits potent antitumor activity against a human lung cancer cell line and its SN-38-resistant variant
22. Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue
23. Sensitive high-performance liquid chromatographic method for the determination of the lactone form and the lactone plus hydroxy-acid forms of the new camptothecin derivative DX-8951 in human plasma using fluorescence detection
24. Validation study of assay method for DX-8951 and its metabolite in human plasma and urine by high-performance liquid chromatography/atmospheric pressure chemical ionization tandem mass spectrometry
25. Irinotecan (CPT-11) high-dose escalation using intensive high-dose loperamide to control diarrhea
26. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer
27. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer
28. Phase I and pharmacokinetic study of the camptothecin analog DX-8951f administered as a 30-minute infusion every 3 weeks in patients with advanced cancer
29. DX-8951f, a hexacyclic camptothecin analog, on a daily-times-five schedule, a Phase I and pharmacokinetic study in patients with advanced solid malignancies
30. Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks
31. Pharmacokinetics of irinotecan and its metabolites SN-38 and APC in children with recurrent solid tumors after protracted low-dose irinotecan
32. Pharmacological correlation between total drug concentration and lactones of CPT-11 and SN-38 in patients treated with CPT-11
33. Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks
34. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients
35. Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in Phase I/II trials
36. Modification of the hydroxy lactone ring of camptothecin: Inhibition of mammalian topoisomerase I and biological activity
37. The important role of albumin in determining the relative human blood stabilities of the camptothecin anticancer drugs
38. The structural basis of camptothecin interactions with human serum albumin: Impact on drug stability
39. A Phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days
40. Pharmacodynamics and pharmacokinetics of a 72-hour infusion of 9-aminocamptothecin in adult cancer patients
41. Phase I and pharmacologic study of high dose of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumors